drugset
drugset / Trial / NCT05101369

A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550

NCT05101369 ↗

Phase 1 Completed 7 enrolled Incyte Corporation
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the absorption, metabolism, and excretion of 86550-106 in healthy males.

Timeline

Start
2022-01-21
Primary completion
2022-03-25
Completion
2022-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject INCB086550 Small molecule 3.7 mbq Oral
Subject INCB086550 Small molecule 400 mg Oral

Indications

No indication recorded.